Podium to Practice: Chicago 2025 – Lung: DeLLphi-304

Podium to Practice: Chicago 2025 – Lung: DeLLphi-304

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Kevin Jao

Studies / Trials Discussed

LBA8008 – Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.

This program has been made possible through unrestricted support from Boehringer Ingelheim.

Studies/trials discussed:

LBA8008 – Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.
Tagged